Show Less

The Public Financing of Pharmaceuticals

An Economic Approach

Edited by Jaume Puig-Junoy

This book provides a complete approach to the economics of financing medicines and policy implications for the efficiency and equity of health systems. In all health systems with majority public financing, pharmaceutical reimbursement is one of the key factors in policies of change and transformation of health services in order to face the future with guarantees of financial sustainability.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 3: Price regulation systems in the pharmaceutical market

J. Puig-Junoy


3. Price regulation systems in the pharmaceutical market J. Puig-Junoy INTRODUCTION Three submarkets of the pharmaceutical market can be distinguished: innovative patented products sold by prescription, products whose patent has expired and are sold by prescription, and products sold without a prescription. The public regulation of prices in the first of these submarkets, and often also in the second, is a fact that can be observed in most Western countries, with certain notable exceptions such as the USA. Concern about the particular characteristics of the pharmaceutical market (for example, the existence of patents and the pharmaceutical industry’s rate of return), together with the desire to provide the majority of the population with access to medicines, regardless of their ability to pay (in many countries the public sector is the main buyer in this market), has led to the fairly widespread adoption of more or less strict price intervention and control policies for pharmaceuticals. Our aim in this chapter is to analyse the effects of price regulation of prescription drugs. First, we review the reasons traditionally given to justify price control policies from the viewpoint of economic theory. Then we describe the price control systems used in Europe, and particularly in Spain. This is followed by an analysis of the main advantages and disadvantages of the systems of direct price fixing, rate of return regulation and price-cap regulation, and they are compared with the optimal prices. Finally, we take a look at the prospects for deregulation and the encouragement of competition...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.